Cefpiramide

Summary

Cefpiramide (CHEMBL1201204) is an approved small-molecule antibacterial drug (ATC J01DD11); indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01DD11
• Indications: 1 condition
• Chemistry: 612.6 Da · C25H24N8O7S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201204
Name	Cefpiramide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	636405
ChEBI	CHEBI:59213
ATC	J01DD11
Molecular formula	C25H24N8O7S2
Molecular weight	612.6
InChIKey	PWAUCHMQEXVFJR-PMAPCBKXSA-N

SMILES: CC1=CC(=O)C(=CN1)C(=O)N[C@H](C2=CC=C(C=C2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O

IUPAC name: (6R,7R)-7-[[(2R)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ChEBI definition: A third-generation cephalosporin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl and (R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It has a broad spectrum of antibacterial activity.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Cefpiramida, Cefpiramide, NSC-759869, WY-44,635, WY-44635, SID50112698, CEFPIRAMIDE, SID144206001, cefpiramide, Cefpiramide (sodium)

Parent form; salt/anhydrous children: CHEMBL1200672

Patent coverage: 3,625 distinct patent families (12,987 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).